Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Inclusion Criteria: * Patients aged 18 years or more with a diagnosis of nasal polyps with Nasal polyp score \>= 4 with minimum score of 2 in each nostril. * Concomitant diagnosis of asthma for a period of at least 6 months prior to screening. * Patients on stable asthma treatment of at least inhaled corticosteroids (any dose) alone for at least 6 months prior to screening or ICS for 6 months prior to screening with any required, inhaled medication (LABA, LAMA) added at least 6 weeks prior to screening. Exclusion Criteria: * Asthma exacerbation, within 6 weeks prior to screening, that required systemic corticosteroids, hospitalization or emergency room visit. * Chronic/maintenance use of oral corticosteroids (OCS) defined as any continuous use of OCS for a period of 1 month or more, within 1 year of screening * Use of biologics for asthma or any other indications, that has the potential to interfere/affect either asthma or nasal polyposis disease progression, within 6 months of screening. * Use of medication for sino-nasal symptoms (antibiotics with or without OCS) within 30 days of screening or during the run-in period. * Use of tetracycline or macrolide antibiotics specifically, within 8 weeks of screening. * History of nasal surgery modifying the structure of the nose such that assessment of the nasal polyp score is not possible. * Patients with baseline ACQ-5≥1.5